{"organizations": ["Aeterna Zentaris"], "uuid": "3f2359c052a7801ee2de5d403be97ac5e964adb9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-biology-technology", "section_title": "Latest Biology Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/biology-technology-1/Aeterna-Zentaris-Zoptarelin-Doxorubicin-Meets-Phase-2-Primary-Endpoint-in-Men-with-Heavily-Pretreated-Castration-and-Taxane-Resistant-Prostate-Cancer-34149-1/", "country": "US", "title": "Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer", "spam_score": 0.0, "site_type": "news", "published": "2015-09-28T19:13:00.000+03:00", "replies_count": 0, "uuid": "3f2359c052a7801ee2de5d403be97ac5e964adb9"}, "author": "", "url": "http://www.bio-medicine.org/biology-technology-1/Aeterna-Zentaris-Zoptarelin-Doxorubicin-Meets-Phase-2-Primary-Endpoint-in-Men-with-Heavily-Pretreated-Castration-and-Taxane-Resistant-Prostate-Cancer-34149-1/", "ord_in_thread": 0, "title": "Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": " ", "external_links": [], "published": "2015-09-28T19:13:00.000+03:00", "crawled": "2015-09-29T16:08:35.648+03:00", "highlightTitle": ""}